References
- RobertCSchachterJLongGVPembrolizumab versus Ipilimumab in Advanced MelanomaN Engl J Med2015372262521253225891173
- KhojaLButlerMOKangSPEbbinghausSJoshuaAMPembroli-zumabJ Immunother Cancer201533626288737
- FujitaKTerashimaTMioTAnti-PD1 Antibody Treatment and the Development of Acute Pulmonary TuberculosisJ Thorac Oncol201611122238224027423391
- LeeJJChanATangTTuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphomaActa Oncol201655451952026754959
- ChuYCFangKCChenHCPericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary AdenocarcinomaJ Thorac Oncol2017128e111e11428748816
- PicchiHMateusCChouaidCInfectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentClin Microbiol Infect201824321621829269089
- DillmanROBarthNMVandermolenLAMahdaviKMcclureSEShould high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?Cancer Biother Radiopharm201227633734322804456
- SharpeAHWherryEJAhmedRFreemanGJThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionNat Immunol20078323924517304234
- LaiCCLeeMTLeeSHRisk of incident active tuberculosis and use of corticosteroidsInt J Tuberc Lung Dis201519893694226162360
- BarberDLMayer-BarberKDFengCGSharpeAHSherACD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibitionJ Immunol201118631598160721172867
- Lázár-MolnárEChenBSweeneyKAProgrammed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosisProc Natl Acad Sci U S A201010730134021340720624978
- TousifSSinghYPrasadDVSharmaPvan KaerLdasGT cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infectionPLoS One201165e1986421589883
- JuradoJOAlvarezIBPasquinelliVProgrammed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosisJ Immunol2008181111612518566376
- SinghAMohanADeyABMitraDKInhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosisJ Infect Dis2013208460361523661793
- SinghAMohanADeyABMitraDKProgrammed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosisClin Exp Immunol2017187226928327665733
- MaierHIsogawaMFreemanGJChisariFVPD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+T lymphocytes in the liverJ Immunol200717852714272017312113
- HotchkissRSMonneretGPayenDImmunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approachLancet Infect Dis201313326026823427891
- LawnSDBekkerLGMillerRFImmune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretroviralsLancet Infect Dis20055636137315919622
- Crum-CianfloneNFImmune reconstitution inflammatory syndromes: what’s new?AIDS Read200616419920616617930
- WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295